Home > Keywords > Thématique > Science

Science

Articles

  • Vect-Horus appoints Claudia Fromond as new Director of R&D
    10 March, by Emmanuelle BETTENDORF

    We are very pleased to welcome Claudia Fromond to Vect-Horus as our new Director of R&D.
    Claudia is a highly regarded pharmacology and translational science leader with extensive experience in R&D. She has successfully overseen first-in-class programs from discovery to Investigational New Drug (IND) application and early clinical development, including a portfolio of seven IND-enabling programs which achieved Phase 1/2 readiness.
    “Claudia has a proven track record of successfully (…)

  • New PCT patent application covering anti Transferrin receptor vectors
    13 October 2020, by Elodie DORMES

    Vect-Horus has filed a PCT patent application covering a library of vectors that target the Transferrin receptor (TfR). This patent strengthens the intellectual property of the Company with a portfolio containing now 6 patent families. This confirms its position as a major player in Blood-Brain Barrier drug delivery technology.

  • Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and Tumors
    22 April 2024, by Emmanuelle BETTENDORF

    Marseille, France, April 22 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the publication of a paper in the open-access scientific journal Pharmaceutics Vol 26 (MDPI).
    The paper, entitled “LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo”, outlines a study which showed how peptides (…)

  • Meet Vect-Horus at Deeptech in Glioblastoma Symposium
    13 January, by Emmanuelle BETTENDORF

    Cédric Malicet, our Oncology Program Director, will be taking part in a panel discussion at the DeepTech in Glioblastoma conference, organized by Paris Saclay Cancer Cluster (PSCC), and taking place January 22 in Villejuif, France.
    Cedric will participate in a pitch session entitled “A comprehensive and diverse front against glioblastoma”, along with representatives from Carthera, TheraSonic, Robeauté, Innov’nCare , with the discussion moderated by Professor Ahmed Idbaih .
    It takes place (…)

  • How blood–brain barrier technology is unleashing CNS therapies
    19 September 2025, by Emmanuelle BETTENDORF

    Nature Research has republished an in-depth article on Vect-Horus in the September issue of Biopharma Dealmakers. The issue focuses on CNS related technologies and therapeutics.
    It’s well worth having a read, or re-read, of this piece, which outlines our VECTrans platform and its potential to transform the treatment of neurodegenerative disorders.
    It also touches on the science and data behind our approach and our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, (…)

  • AD/PD 2019​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in LISBON
    28 January 2019, by Jonathan NOWAK

    Marion DAVID and Romy COHEN will present the “Development of vectors that cross the blood brain barrier to enhance CNS drug delivery in neurodegenerative diseases” in session A: β-Amyloid Diseases poster n°ADPD9-1832

  • Meet Vect-Horus at OTS, Barcelona, October 22-25, 2023
    12 October 2023, by Emmanuelle BETTENDORF

    Vect-Horus team will attend the 19th Annual Meeting of the Oligonucleotide Therapeutics Society from October 22nd to 25th, 2023, in Barcelona.
    We are pleased to announce that Guillaume Jacquot, Program Director, Brain & Tissue Targeting of Oligonucleotides, will give a talk entitled “TfR-targeted functional delivery of oligonucleotides to CNS tissues by local and systemic administration” on Tuesday, 24th and Emmanuelle Bettendorf, Senior Business Developer, will also be there and (…)

  • Vect-Horus Appoints Dr Jean-Manuel PEAN as Chief Scientific Officer
    3 April 2023, by Elodie DORMES

    Marseille, April 3rd, 2023 - VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer. In this role, he will lead the Company’s scientific programs and will be a member of the Management Committee of Vect-Horus.
    Alexandre Tokay, CEO and co-founder of VECT-HORUS said: "We are very pleased to have Jean-Manuel as our (…)

  • Vect-Horus will join the ARVO Annual Meeting
    17 April 2024, by Emmanuelle BETTENDORF

    We’re excited to present a poster on our targeted drug delivery technology at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting, taking place in Seattle, WA, USA from May 5-9, 2024.
    The poster is titled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”.
    It will be available at ARVO on May 7, 2024, from 3:30pm to 5:15pm PDT Posterboard Number 3992 - B0036 and Session (…)

  • TIDES Asia, March 2-5 2021 - 100% Virtual
    4 March 2021, by Elodie DORMES

    Guillaume JACQUOT PharmD, PhD, will present last company results on extra-hepatic delivery of oligonucleotides.